Biogen, Ionis: Targeting Tau Shows Promise for Potential New Gen Alzheimer's Treatment

 

• In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.
  

• First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.

• Recruitment is underway for the Phase 2 CELIA study further investigating clinical efficacy and safety.

https://finance.yahoo.com/news/data-biogen-investigational-antisense-oligonucleotide-145100807.html